Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study.

MLA

Li, Wei, et al. “Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study.” Journal of Clinical Oncology, vol. 42, no. 22, Aug. 2024, pp. 2660–70. EBSCOhost, https://doi.org/10.1200/JCO.24.00731.

APA

Li, W., Xiong, A., Yang, N., Fan, H., Yu, Q., Zhao, Y., Wang, Y., Meng, X., Wu, J., Wang, Z., Liu, Y., Wang, X., Qin, X., Lu, K., Zhuang, W., Ren, Y., Zhang, X., Yan, B., Lovly, C. M., & Zhou, C. (2024). Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study. Journal of Clinical Oncology, 42(22), 2660–2670. https://doi.org/10.1200/JCO.24.00731

Chicago

Li, Wei, Anwen Xiong, Nong Yang, Huijie Fan, Qitao Yu, Yanqiu Zhao, Yongsheng Wang, et al. 2024. “Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study.” Journal of Clinical Oncology 42 (22): 2660–70. doi:10.1200/JCO.24.00731.